Professor Neil Garragher and Dr Simon Wilkinson at the Institute of Genetics and Cancer at the University of Edinburgh are investigating potential targeted therapies that interfere with molecular processes that pancreatic cancer require for survival. Two exciting targets are the metabolic process called autophagy, and a process that controls how active gernes are (histone methylation). They are employing a drug that they have recently discovered, and which blocks histone methylation. The research will determine the mechanism of action of a potential novel therapeutic in the pancreatic cancer with a view to evidencing future translational research into clinical studies.